与MASLD相关的肝脏重大不良结果之前的时间性并发症模式:瑞典全国性基于人口的病例控制研究
Joost Boeckmans1,2, Linnea Widman1, Rickard Strandberg1
1Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
BMJ public health
|November 20, 2025
概括
与代谢功能障碍相关的脂肪性肝病 (MASLD) 患有主要不良肝结果 (MALOs) 的患者往往先前患有心脏病和睡眠障碍. 这些并发症,包括心脏代谢风险因素,出现在MALO多年前.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 心脏病学 心脏病学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 在代谢功能障碍相关的脂肪性肝病 (MASLD) 中,主要不良肝结局 (MALOs) 之前的并发症尚不清楚.
- MASLD是一个日益严重的全球健康问题,与肝脏相关的显著发病率有关.
研究的目的:
- 在患有MASLD的患者中识别和描述先于MALO的并发症模式.
- 为了比较 MASLD 患者与 MALO 患者之间的并发症患病率,以及与人口对照.
主要方法:
- 使用瑞典国家患者登记册 (2006-2022) 的回顾性队列研究.
- 与MALO相关的MALO患者与没有MALO的MALO患者和人口对照进行匹配.
- 国际疾病分类的分层聚类 - - 10个代码确定了共患病;计算了MALO的中位数时间.
主要成果:
- 996名与MASLD相关的MALO患者与3921名MASLD对照和9056名人口对照进行了匹配.
- 患有MALO的患者中位数为9种并发症类别,特别是包括2型糖尿病 (49%) 和高血压 (56%) 在内的心脏代谢集群,诊断为~6年前.
- 在8-14%的患者中,心脏病 (心力衰竭,心房动/动,心肌梗塞,心痛) 和睡眠障碍在MALO之前4-8年.
结论:
- 与MASLD相关的MALO患者经常是多病症患者,心脏病和睡眠障碍是显著的先决条件.
- 心脏代谢风险因素的存在以及特定的心脏和睡眠障碍的存在使得MALO风险更高的个体具有特征.
- 这些发现可能有助于早期的病例发现和MASLD患者的干预策略,这些患者有不良肝脏结果的风险.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
1.6K
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
11.0K
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
01:26Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
01:29Therapeutic Drug Monitoring: Affecting Factors
183
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
183